Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.

Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A.

Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12578-83.

2.

DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains.

Veldic M, Caruncho HJ, Liu WS, Davis J, Satta R, Grayson DR, Guidotti A, Costa E.

Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):348-53.

3.

An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.

Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P, Sharma R, Grayson DR, Costa E, Guidotti A.

Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):17095-100.

4.
5.

DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures.

Noh JS, Sharma RP, Veldic M, Salvacion AA, Jia X, Chen Y, Costa E, Guidotti A, Grayson DR.

Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1749-54.

6.

Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters.

Dong E, Guidotti A, Grayson DR, Costa E.

Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4676-81.

7.

The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (+/-) in schizophrenia.

Grayson DR, Chen Y, Costa E, Dong E, Guidotti A, Kundakovic M, Sharma RP.

Pharmacol Ther. 2006 Jul;111(1):272-86. Review.

PMID:
16574235
8.

DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients.

Dong E, Ruzicka WB, Grayson DR, Guidotti A.

Schizophr Res. 2015 Sep;167(1-3):35-41. doi: 10.1016/j.schres.2014.10.030.

9.

The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes.

Kundakovic M, Chen Y, Guidotti A, Grayson DR.

Mol Pharmacol. 2009 Feb;75(2):342-54. doi: 10.1124/mol.108.051763.

10.

Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice.

Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E, Guidotti A.

Biol Psychiatry. 2005 Mar 1;57(5):500-9.

PMID:
15737665
11.

Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice.

Matrisciano F, Tueting P, Dalal I, Kadriu B, Grayson DR, Davis JM, Nicoletti F, Guidotti A.

Neuropharmacology. 2013 May;68:184-94. doi: 10.1016/j.neuropharm.2012.04.013.

12.

Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation.

Dong E, Grayson DR, Guidotti A, Costa E.

Epigenomics. 2009 Oct;1(1):201-11. doi: 10.2217/epi.09.2.

PMID:
22122643
13.

Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.

Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E.

Trends Pharmacol Sci. 2009 Feb;30(2):55-60. doi: 10.1016/j.tips.2008.10.010.

PMID:
19110320
14.

GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability.

Costa E, Grayson DR, Mitchell CP, Tremolizzo L, Veldic M, Guidotti A.

Crit Rev Neurobiol. 2003;15(2):121-42. Review.

PMID:
14977367
15.

Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation.

Dong E, Nelson M, Grayson DR, Costa E, Guidotti A.

Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13614-9. doi: 10.1073/pnas.0805493105.

16.

Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study.

Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E.

Arch Gen Psychiatry. 2000 Nov;57(11):1061-9. Erratum in: Arch Gen Psychiatry 2002 Jan;59(1):12. DiGiorgi Gerevini V [corrected to Di-Giorgi-Gerevini V].

PMID:
11074872
17.

Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.

Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M, Shafa R, Glatt SJ, Nguyen G, Ponte JF, Thiagalingam S, Tsuang MT.

Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):60-6.

PMID:
15717292
18.

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.

Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, Zhang X, Costa E.

Psychopharmacology (Berl). 2005 Jul;180(2):191-205. Review.

PMID:
15864560
19.
20.

Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.

Veldic M, Kadriu B, Maloku E, Agis-Balboa RC, Guidotti A, Davis JM, Costa E.

Schizophr Res. 2007 Mar;91(1-3):51-61.

Items per page

Supplemental Content

Support Center